Keyphrases
Sporadic Late-onset Nemaline Myopathy
33%
Progressive Paralysis
33%
Motor Neuron Disease
33%
Passive Transfer
33%
Approved Drugs
33%
Sporadic Patient
33%
GLA Gene
33%
Cardiac Phenotype
33%
Pimavanserin
33%
Axotomy
33%
Spinal Motoneurons
33%
Mouse Modeling
33%
Rozanolixizumab
33%
AMPA Receptor Antagonist
33%
Axon Terminal
33%
Talampanel
20%
Nemaline Rods
16%
5-HT2A Agonist
16%
5-HT2A
16%
Superoxide Dismutase 1 (SOD1)
13%
Oculomotor Neuron
13%
Brain Control Interface
11%
Three-dimensional Control
11%
Thymic Follicular Hyperplasia
8%
Neuromuscular Transmission
8%
Myofibril
8%
Nemaline Myopathy
8%
Antipsychotic Clozapine
8%
Parkinson's Disease Psychosis
8%
Distress Symptoms
8%
Emerging Therapies
8%
Inverse Agonist
8%
Progressive Neurodegeneration
8%
Non-motor Symptoms
8%
LysoGb3
8%
Microglial Cells
8%
Gliosis
6%
Motor Nerve Terminal
6%
Glial Activation
6%
Human Immunoglobulin G
6%
Chelated Calcium
6%
Mutant Superoxide Dismutase 1
6%
Calcium Elevation
6%
Perikaryon
6%
Calcium Buffer
6%
Calcium-permeable
6%
Autonomous Motor
6%
Spinal Motor Neurons
6%
Receptor Subunits
6%
SOD1G93A
6%
Neuroscience
Amyotrophic Lateral Sclerosis
100%
Synaptic Vesicle
33%
Motor Neuron Disease
33%
Axon
33%
Tongue Control
33%
Copper Zinc Superoxide Dismutase
25%
Chemokine
20%
Neuromuscular Disorder
16%
Calcium-Binding Protein
13%
Intraperitoneal Injection
11%
Gliosis
6%
Human Immunoglobulin
6%
Calcium Buffering
6%
Receptor Subunit
6%
Perikaryon
6%
Immunoglobulin G
5%
Myelitis
5%
Transverse Myelitis
5%
Aquaporin 4 Antibody
5%
Optic Neuritis
5%
Pharmacology, Toxicology and Pharmaceutical Science
Myasthenia gravis
33%
Pimavanserin
33%
Placebo
33%
Rozanolixizumab
33%
Inverse Agonist
16%
Serotonin 2A Receptor
11%
Adverse Event
7%
Optic Neuritis
5%
Aquaporin 4 Antibody
5%
Squamous Cell Lung Carcinoma
5%